A real-world study of the optimal duration of CPX-351 treatment in patients with AML

The real-world safety and efficacy of CPX-351 in patients with AMLПодробнее

CPX-351 vs. HMA plus venetoclax in the treatment of patients with AMLПодробнее

Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AMLПодробнее

Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AMLПодробнее

Intensive chemotherapy: why the modern approach of CPX-351 is important for cure in AMLПодробнее

Safety and efficacy of CPX-351 in newly diagnosed AML patients under the age of 60Подробнее

Updates on CPX-351: real world experiences and studies in MDSПодробнее

What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?Подробнее

Analyzing the cost-effectiveness of CPX-351 in patients with AMLПодробнее

CPX-351 for secondary AML: pharmacokinetics, administration & impact on treatmentПодробнее

CPX-351 with venetoclax in R/R AML: results of a Phase Ib studyПодробнее

What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?Подробнее

Improved understanding of CPX-351 in AML: impact of HCT & final EAP resultsПодробнее

What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?Подробнее

Role of CPX-351 in Acute Myeloid LeukemiaПодробнее

CPX-351 and gemtuzumab ozogamicin in R/R AML and MDSПодробнее

Evaluating CPX-351 against 7+3 in older newly diagnosed AMLПодробнее

Predicting the outcomes of patients with AML treated with CPX-351 based on ELN risk stratificationПодробнее

CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AMLПодробнее